1907 studies found for:    Open Studies | "Breast Neoplasms"
Show Display Options
Rank Status Study
1 Recruiting Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer
Conditions: Stage 0 Breast Carcinoma;   Breast Neoplasms;   Stage I Breast Carcinoma;   Stage II Breast Carcinoma;   Stage III Breast Carcinoma
Interventions: Drug: Metformin;   Drug: Omega-3 fatty acids
2 Recruiting Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Conditions: Breast Cancer;   Breast Neoplasm;   Breast Tumor;   Cancer of the Breast
Intervention: Radiation: Proton Radiotherapy
3 Recruiting GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Triple Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI;   Drug: GDC -0941
4 Recruiting Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer Patients Who Have Failed an Anthracycline (CAT)
Conditions: Breast Neoplasms;   Breast Cancer
Interventions: Drug: Taxane;   Drug: Taxotere;   Drug: Abraxane;   Drug: Ixabepilone
5 Recruiting Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
Conditions: Breast Neoplasms;   Malignant Tumor of the Breast
Interventions: Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine
6 Recruiting Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors
Conditions: Benign Breast Neoplasm;   Ductal Breast Carcinoma In Situ;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma In Situ;   Paget Disease of the Breast;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Docosahexaenoic Acid;   Other: Laboratory Biomarker Analysis;   Other: Placebo
7 Recruiting Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
Conditions: Breast Cancer;   Breast Carcinoma;   Breast Tumors;   Malignant Neoplasm of Breast
Interventions: Drug: Paclitaxel;   Drug: Alisertib
8 Recruiting Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Conditions: Metastatic Breast Cancer;   Breast Carcinoma;   HER-2 Positive Breast Cancer
Interventions: Drug: Ruxolitinib;   Drug: Trastuzumab
9 Recruiting Proton Radiation for Stage II/III Breast Cancer
Conditions: Breast Cancer;   Breast Neoplasm;   Breast Tumor;   Cancer of the Breast
Intervention: Radiation: Proton Radiotherapy
10 Not yet recruiting Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer
Conditions: Ductal Breast Carcinoma in Situ;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Ductal Breast Carcinoma With Predominant Intraductal Component;   Lobular Breast Carcinoma in Situ;   Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate;   Mucinous Ductal Breast Carcinoma;   Papillary Ductal Breast Carcinoma;   Progesterone Receptor-positive Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Tubular Ductal Breast Carcinoma
Interventions: Radiation: accelerated partial breast irradiation;   Radiation: intensity-modulated radiation therapy;   Radiation: image-guided radiation therapy;   Procedure: therapeutic conventional surgery;   Other: questionnaire administration;   Other: laboratory biomarker analysis
11 Not yet recruiting Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Conditions: Breast Cancer;   Cancer of Breast;   Breast Neoplasms;   Cancer of the Breast
Interventions: Device: Oncotype DX® Breast Cancer Assay;   Behavioral: FACT-B;   Drug: Goserelin;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Fulvestrant;   Drug: Tamoxifen
12 Recruiting Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy
Conditions: Triple Negative Breast Cancer;   Triple-Negative Breast Cancer;   Triple Negative Breast Neoplasms
Intervention: Biological: Personalized polyepitope DNA vaccine
13 Not yet recruiting Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Conditions: Triple Negative Breast Cancer;   Triple Negative Breast Neoplasms;   Triple-Negative Breast Cancer
Interventions: Biological: Personalized synthetic long peptide vaccine (Poly ICLC);   Drug: Poly ICLC
14 Recruiting A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients
Conditions: Taxane-induced Peripheral Neuropathy;   Chemotherapy-induced Peripheral Neuropathy (CIPN);   Early-Stage Breast Carcinoma;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Interventions: Procedure: Immediate Acupuncture Group;   Procedure: Delayed Acupuncture Group
15 Recruiting Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: questionnaire administration
16 Recruiting Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Conditions: HER2-negative Breast Cancer;   Inflammatory Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Romidepsin;   Drug: Abraxane
17 Not yet recruiting [18F]FES PET/CT in Endocrine Refractory Breast Cancer
Conditions: Estrogen Receptor Positive Breast Cancer;   Breast Neoplasm;   Metastatic Breast Cancer
Intervention: Drug: [18F]FES
18 Recruiting Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
Conditions: Ductal Breast Carcinoma in Situ;   Lobular Breast Carcinoma in Situ;   Male Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Dietary Supplement: omega-3 fatty acid;   Other: placebo;   Other: laboratory biomarker analysis
19 Recruiting BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: PI3K inhibitor BYL719;   Drug: letrozole;   Other: laboratory biomarker analysis;   Other: pharmacological studies
20 Recruiting Olaparib and Radiotherapy in Inoperable Breast Cancer
Conditions: Locally Advanced Malignant Neoplasm;   Inflammatory Breast Carcinoma;   Triple-Negative Invasive Breast Carcinoma
Interventions: Radiation: radiotherapy;   Drug: olaparib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years